ArticleJournal of virology1995
Large hepatitis delta antigen in packaging and replication inhibition: role of the carboxyl-terminal 19 amino acids and amino-terminal sequences.
Article in Journal of virology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Comprehensive Analysis of Mutations in the Hepatitis Delta Virus Genome Based on Full-Length Sequencing in Individuals Infected with Genotype 3 in Brazil.Archives of virology · 2026Article
- Review
- Differential impact of hepatitis delta virus replication and expression of viral antigens on the cellular kinome profile.Cell communication and signaling : CCS · 2025Article
- Sequence analysis of the hepatitis D virus across genotypes reveals highly conserved regions amidst evidence of recombination.Virus evolution · 2025Article
- Article
- Review
- Hepatitis Delta: Current Knowledge and Future Directions.Gastroenterology & hepatology · 2022Article
- Role of Host-Mediated Post-Translational Modifications (PTMs) in RNA Virus Pathogenesis.International journal of molecular sciences · 2020Review
- Statin inhibits large hepatitis delta antigen-Smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion.Journal of biomedical science · 2020Article
- Hepatitis Delta Virus Alters the Autophagy Process To Promote Its Genome Replication.Journal of virology · 2020Article
- Chronic hepatitis delta: A state-of-the-art review and new therapies.World journal of gastroenterology · 2019Review
- Anti-Transcription Factor RNA Aptamers as Potential Therapeutics.Nucleic acid therapeutics · 2016Review
- Identification of a binding site for ASF/SF2 on an RNA fragment derived from the hepatitis delta virus genome.PloS one · 2013Article
- Article
- Modification of small hepatitis delta virus antigen by SUMO protein.Journal of virology · 2010Article
- Transcription of subgenomic mRNA of hepatitis delta virus requires a modified hepatitis delta antigen that is distinct from antigenomic RNA synthesis.Journal of virology · 2008Article
- A tryptophan-rich motif in the carboxyl terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis delta virus particles.Journal of virology · 2006Article
- RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus.Journal of virology · 2005Review
- Molecular phylogenetic analysis of Iranian HDV complete genome.Virus genes · 2005Article
- Hepatitis delta virus antigen is methylated at arginine residues, and methylation regulates subcellular localization and RNA replication.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis delta virus (HDV) encodes two proteins, the small delta antigen (SHDAg) and large delta antigen (LHDAg). The latter is identical to the former except for the presence of additional 19 amino acids at the C terminus. While SHDAg is required for HDV replication, LHDAg inhibits replication and, together with hepatitis B surface antigen (HBsAg), is required for the assembly of HDV. The last 19 C-terminal amino acids of LHDAg are essential for HDV assembly. Most of LHDAg (amino acids 19 to 146 and 163 to 195) had been shown to be dispensable for packaging with HBsAg. To discern whether the last 19 C-terminal amino acids solely constitute the signal for packaging with HBsAg, we constructed two LHDAg deletion mutants and tested their abilities to be packaged with HBsAg in cotransfection experiments. We found that deletion of amino acids 2 to 21 and 142 to 165 did not affect LHDAg packaging. This result suggested that only the last 19 C-terminal amino acids of LHDAg are required for packaging. We further constructed two plasmids which expressed c-H-ras with or without additional 19 C-terminal amino acids identical to those in LHDAg. Only c-H-ras with additional 19 amino acids could be cosecreted with HBsAg in the cotransfection experiment. This result confirmed that the C-terminal 19 amino acids are the packaging signal for HBsAg. We also tested the trans activation activity and trans-dominant inhibitory activity of the deletion mutants of SHDAg and LHDAg, respectively. In contrast to deletion of amino acids 142 to 165, deletion of amino acids 2 to 21 impaired the trans-dominant inhibitory activity of LHDAg. Deletion of amino acids 2 to 21 and 142 to 165 did not affect the trans activation activity of SHDAg. This result suggested that a functional domain which is important for the trans-dominant inhibitory activity of LHDAg exists in the amino terminus of HDAg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.